Explore

TrendlineTrendline
China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials

China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials

China's 30-Day Drug Approval Process Attracts U.S. Biotech First-in-Human Trials
TrendlineTrendline
FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies

FDA Anticipates Key Decisions in November for Summit/Akeso, Capricor, and Vertex Therapies
TrendlineTrendline
Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements
TrendlineTrendline
AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges

AI Integration in Clinical Trials Shows Early Efficiency Gains, Faces Scaling Challenges
TrendlineTrendline
BioAge Labs Reports Positive Phase 1 Trial Results for BGE-102 and Advances to Phase 2 for Cardiometabolic Diseases

BioAge Labs Reports Positive Phase 1 Trial Results for BGE-102 and Advances to Phase 2 for Cardiometabolic Diseases

BioAge Labs Reports Positive Phase 1 Trial Results for BGE-102 and Advances to Phase 2 for Cardiometabolic Diseases
Rapid ReadRapid Read
Gilead and Kite Announce New Data on Cancer and Autoimmune Disease Treatments at ASH 2026

Gilead and Kite Announce New Data on Cancer and Autoimmune Disease Treatments at ASH 2026

Gilead Sciences, Inc. and its company Kite have announced that they will present 23 new data presentations, including seven oral presentations, at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, scheduled from December 12–15, 2026. These presentations will highlight significant advancements across Gilead and Kite’s pipeline and portfolio, focusing on treatments for blood cancers and autoimmune disorders. Key data includes 18-month minimum follow-up results for anitocabtagene autoleucel (anito-cel) in relapsed or refractory multiple myeloma (RRMM) from the pivotal Phase 2 iMMagine-1 study. This data forms the basis of a Biologics License Application (BLA) currently under review by the U.S. Food and Drug Administration (FDA), with a target decision date of December 23, 2026. Additionally, five-year follow-up data for Yescarta® (axicabtagene ciloleucel) in first-line high-risk large B-cell lymphoma (LBCL) will be presented, along with early clinical results for KITE-753 in B-cell ...
Rapid ReadRapid Read
Antengene Initiates Phase I ATTRACT Study for Autoimmune Disease Treatment ATG-201 in China and Australia

Antengene Initiates Phase I ATTRACT Study for Autoimmune Disease Treatment ATG-201 in China and Australia

Antengene Corporation Limited, a global biotech company, has announced that the first patient has been dosed in China for its Phase I ATTRACT study. This study evaluates ATG-201, Antengene's proprietary CD19 × CD3 bispecific T-cell engager antibody (TCE), in adult patients suffering from B cell-mediated autoimmune diseases. The study is being conducted in both China and Australia, with ATG-201 having received approval from the Human Research Ethics Committee (HREC) in Australia and completing the Clinical Trial Notification (CTN) process with the Therapeutic Goods Administration (TGA). ATG-201 is designed to precisely target and eliminate CD19-expressing B cells using steric hindrance masking technology, aiming to leverage the body's immune system for treating these diseases. The ATTRACT study, led by Professor Zhanguo Li, will assess the safety, tolerability, and preliminary efficacy of ATG-201 in two parts: Dose Escalation (Part I) and Dose Expansion (Part II).
TrendlineTrendline
Orrick Advises Nxera Pharma in $1.47 Billion Global License Agreement with AbbVie for IBD Drug

Orrick Advises Nxera Pharma in $1.47 Billion Global License Agreement with AbbVie for IBD Drug

Orrick Advises Nxera Pharma in $1.47 Billion Global License Agreement with AbbVie for IBD Drug
Rapid ReadRapid Read
MHRA Issues New Guidance on Non-OECD Clinical Trial Data Assessment to Support UK Research

MHRA Issues New Guidance on Non-OECD Clinical Trial Data Assessment to Support UK Research

The Medicines and Healthcare products Regulatory Agency (MHRA) has published new guidance detailing its patient-centered approach to assessing clinical trial applications that rely on non-clinical safety data generated outside the Organisation for Economic Co-operation and Development (OECD) Mutual Acceptance of Data framework. This guidance, issued on November 4, 2026, aims to support a more risk-proportionate approach to clinical research, thereby advancing the development of new treatments and increasing opportunities for UK patients to participate in trials. While data generated within the OECD framework remains the expected standard, the MHRA will now consider non-OECD data in individual applications, particularly when supported by evidence and the circumstances of the intended patient population.
Rapid ReadRapid Read
Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

Kamau Therapeutics, a California-based biotech company, has released preliminary clinical data for its gene-edited sickle cell disease (SCD) therapy, nula-cel. The data, to be presented at the American Society of Hematology (ASH) conference, show precise correction of the SCD mutation in the β-globin gene in three patients. These patients have also demonstrated restored expression of adult hemoglobin (HbA) and have become transfusion-independent, experiencing no pain crises since receiving their gene-edited hematopoietic stem cells (HSCs). Unlike FDA-approved Casgevy, which increases fetal hemoglobin (HbF), Kamau's nula-cel therapy directly replaces the SCD mutation using homology-directed repair (HDR). The company reports that sickle hemoglobin (HbS) levels fell below 20% of total hemoglobin in two patients who reached the 6-month post-infusion mark. The Phase I/II RESTORE trial is currently enrolling 15 participants.
Rapid ReadRapid Read
Resolution Therapeutics Presents Positive Interim Data for Regenerative Macrophage Therapy RTX001 in End-Stage Liver Disease

Resolution Therapeutics Presents Positive Interim Data for Regenerative Macrophage Therapy RTX001 in End-Stage Liver Disease

Resolution Therapeutics has announced positive interim six-month data from its Phase I/II EMERALD trial, which is evaluating RTX001, an investigational autologous engineered regenerative macrophage therapy (RMT). The trial focuses on patients suffering from end-stage liver disease (ESLD). The data indicates a signal of efficacy in clinical outcomes such as death, liver transplant, and hepatic decompensation. RTX001 was well tolerated by patients, with no serious adverse reactions related to infusion and no severe adverse events attributed to the treatment. Furthermore, prospectively defined biomarkers showed reductions in inflammation and fibrogenesis markers, aligning with the predicted mechanism of regenerative macrophages. The company plans to discuss the program with the FDA and advance RTX001 towards a planned U.S. pivotal trial. These findings will be presented at The Liver Meeting 2026 of the American Association for the Study of Liver Diseases (AASLD) in Denver, Colorado.
TrendlineTrendline
MRM Health and Biocodex Partner to Enhance Commercial Supply for Microbiome-Based Medicines

MRM Health and Biocodex Partner to Enhance Commercial Supply for Microbiome-Based Medicines

MRM Health and Biocodex Partner to Enhance Commercial Supply for Microbiome-Based Medicines